NeoStem (AMEX: NBS), FY10 Results
Revenues for FY10 were $69.8M compared with $11.6M for 2009.
FY10 revenues increased 13% over FY09 pro forma revenues of $61.7M. 2010 was the first full year that results were included for NBS’ 51% owned subsidiary, Suzhou Erye Pharmaceutical Co. Ltd. (“Erye”), were included in results. Net cash used in operating activities for FY10 was $8.5M compared to $8.4 M for the year ended FY09. In FY10, NBS invested $16.4M in capital expenditures primarily related to the construction of a new pharmaceutical manufacturing facility at Erye. (Full filing breakdown next week)
- Cash and cash equivalents at 12/31/10 were $15.6M.
Categories: AMEX: NBS, FY10 Results, Stem Cell Research
